Alx Oncology Holdings (ALXO) Other Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Other Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 4535.42% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 4535.42% YoY), and the FY2025 full-year result was $2.3 million, up 1459.06% from the prior year.
• Other Accumulated Expenses declined to $2.2 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.5 million in Q3 2025 to a low of $40000.0 in Q2 2025.
• A 5-year average of $1.2 million and a median of $892000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 93.24% in 2024 and surged 4535.42% in 2026, its largest moves.
• Tracing ALXO's Other Accumulated Expenses over 5 years: stood at $2.0 million in 2022, then climbed by 7.56% to $2.2 million in 2023, then slumped by 93.24% to $149000.0 in 2024, then soared by 1459.06% to $2.3 million in 2025, then declined by 4.22% to $2.2 million in 2026.
• Business Quant data shows ALXO's Other Accumulated Expenses at $2.2 million in Q1 2026, $2.3 million in Q4 2025, and $2.5 million in Q3 2025.